Hematological malignancies are a diverse group of disorders. The mechanisms contributing to the development of these disorders are still poorly understood. Certain leukemias that are resistant to current therapies present a particularly difficult challenge.
Molecular medicine is expected to provide solutions to these problems, but identifying new molecules relevant to a particular disorder and developing targeted treatments still requires a great deal of research. Biobank research can speed up the work of identifying such molecular factors.